glp-1 microdosing for menopause GLP-1s: Benefits Management Microdosing GLP 1 and the

When the study group was stratified by BMI, adults without obesity, those with class I obesity (BMI: 30-34.99 kg/m2) and those with class II obesity (BMI: 35-39.99 kg/m2) were less likely to have all-cause hospital admissions, ED visits, undergo an endoscopic procedure, receive a prescription for a prokinetic, and receive a laxative prescription if they used an incretin-based drug compared with nonusers

FDA Clears First Oral GLP-1 for Weight Loss

35 The mechanisms underlying the effect of GLP-1 receptor agonists on OSA remain incompletely understood but are believed to be largely mediated through weight reduction.[45] OFF-LABEL AND INVESTIGATIONAL USES OF GLP-1RAS Investigational and off-label indications of GLP1-RAs are conditions that may have some evidence of benefit, but which currently lack FDA approval for a particular medication

for the treatment of intrahepatic cholestasis in adults (18 years) with pre-cirrhotic and cirrhotic liver disease

P.SwickJ

Another incretin hormone, peptide YY (PYY), which is also secreted along with GLP-1 and GLP-2, has the most prominent role in appetite suppression, but recent studies have also shown that PYY has a strong inhibitory effect on bone formation (Jensen et al., 2021